Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based
Authors:
- 1 May 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (9) , 4471-4476
Abstract
Vitamin K antagonists (VKAs) are effective antithrombotic agents and advocated in guidelines for the management of cardiovascular disease. However, in the trials underlying these guidelines, many patients were excluded. We performed a case-control study in 993 patients receiving VKAs, who required hospitalization for bleeding, and contrasted them to 993 matched control patients on VKAs, who were hospitalized for an infection. We analyzed whether patients and controls would have been eligible for the clinical trials on which their indication for anticoagulation was based, and estimated the risk of hemorrhage associated with exclusion criteria as applied in those trials. Approximately one quarter (23% [95% CI: 21%-26%]) of controls had one or more exclusion criteria for the trials, supporting the use of anticoagulation for their condition. Forty percent of patients presenting with bleeding had one or more exclusion criteria (95% CI: 37%-43%). Having one exclusion criterion resulted in a 2.9-fold increased risk of bleeding (95% CI: 2.2-3.9), and this risk increased sharply when more than one exclusion criterion was present. VKAs are often prescribed to patients who would not have qualified for clinical trials, and in these patients a careful consideration should be made regarding the expected efficacy and the risk of bleeding.Keywords
This publication has 29 references indexed in Scilit:
- Clinical Consequences of Generic Warfarin Substitution: An Ecological Study2006
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2006
- AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 UpdateCirculation, 2006
- Contrast sonography for detection of vesicoureteral refluxThe Lancet, 1994
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1992
- Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolismThe Lancet, 1992
- Stroke Prevention in Atrial Fibrillation Study. Final results.Circulation, 1991
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATIONThe Lancet, 1989